

## Mpox vaccine and infection-driven human immune signatures

Hallie Cohn<sup>1\*</sup>, Nathaniel Bloom<sup>2\*</sup>, Gianna Cai<sup>1\*</sup>, Jordan Clark PhD<sup>1\*</sup>, Alison Tarke PhD<sup>2</sup>, Maria C Bermúdez-González MPH<sup>1,8</sup>, Deena Altman MD<sup>10</sup>, Luz Amarilis Lugo MD<sup>10</sup>, Francisco Pereira Lobo PhD<sup>3</sup>, Susanna Marquez<sup>4</sup>, PVI study group<sup>1,8</sup>, Jin-Qiu Chen PhD<sup>5</sup>, Wenlin Ren PhD<sup>5</sup>, Lili Qin PhD<sup>5</sup>, Shane Crotty PhD<sup>2,6</sup>, Florian Krammer PhD<sup>1,8,9</sup>, Alba Grifoni PhD<sup>2</sup>, Alessandro Sette PhD<sup>2,7</sup>, Viviana Simon MD/PhD<sup>1,8,9,10,11†</sup>, Camila H. Coelho PhD<sup>1,8,12†</sup>

- 1- Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 2- Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA, USA
- 3- Department of Genetics, Ecology and Evolution, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- 4- Doctoral Program in Design, Manufacture, and Management of Industrial Projects, Universitat Politècnica de València, Valencia, Spain
- 5- ACROBioSystems, Beijing, China
- 6- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA, USA
- 7- Department of Pathology, University of California, San Diego, La Jolla, CA, USA
- 8- Center for Vaccine Research and Pandemic Preparedness, Icahn School of Medicine at Mount Sinai New York, NY, USA
- 9- Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 10- Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 11- The Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 12- Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

\*These authors contributed equally

†Corresponding authors: [viviana.simon@mssm.edu](mailto:viviana.simon@mssm.edu), [camila.coelho@mssm.edu](mailto:camila.coelho@mssm.edu)

Address: 1 Gustave Levy Place, Annenberg 16<sup>th</sup> floor - New York, NY 10029

Phone number: 212-241-253

44 **Abstract**

45

46 **Background**

47 Mpox (formerly known as monkeypox) outbreaks outside endemic areas peaked in July 2022,  
48 infecting > 85,000 people and raising concerns about our preparedness against this emerging  
49 viral pathogen. Licensed and approved for mpox, the JYNNEOS vaccine has fewer side effects  
50 than previous smallpox vaccines and demonstrated efficacy against mpox infection in humans.  
51 Comparing JYNNEOS vaccine- and mpox-induced immunity is imperative to evaluate  
52 JYNNEOS' immunogenicity and inform vaccine administration and design.

53 **Methods**

54 We examined the polyclonal serum (ELISA) and single B cell (heavy chain gene and  
55 transcriptome data) antibody repertoires and T cells (AIM and ICS assays) induced by the  
56 JYNNEOS vaccine as well as mpox infection.

57 **Findings**

58 Gene-level plasmablast and antibody responses were negligible and JYNNEOS vaccinee sera  
59 displayed minimal binding to recombinant mpox proteins and native proteins from the 2022  
60 outbreak strain. In contrast, recent mpox infection (within 20-102 days) induced robust serum  
61 antibody responses to A29L, A35R, A33R, B18R, and A30L, and to native mpox proteins,  
62 compared to vaccinees. JYNNEOS vaccine recipients presented comparable CD4 and CD8 T  
63 cell responses against orthopox peptides to those observed after mpox infection.

64 **Interpretation:**

65 JYNNEOS immunization does not elicit a robust B cell response, and its immunogenicity may  
66 be mediated by T cells.

67 **Funding:**

68 Research reported in this publication was supported, in part, by the National Cancer Institute  
69 of the National Institutes of Health under Award Number U54CA267776, U19AI168631(VS), as  
70 well as institutional funds from the Icahn School of Medicine.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

## 86 Introduction

87  
88 Mpox (formerly known as monkeypox) is a zoonotic infection caused by an orthopoxvirus  
89 (OPXV). This viral genus includes smallpox, which has dramatically affected humanity for  
90 centuries. As we progressed toward its eradication in the 1980s, mpox became the most  
91 concerning OPXV for humans, causing multiple outbreaks in Central and West Africa since  
92 1970, and its first outbreak outside Africa (in the US) in 2003<sup>1</sup>. The 2022 global mpox outbreak  
93 infected > 85,000 people, providing an unprecedented opportunity to study human immune  
94 responses to mpox outside Africa. While the World Health Organization reported that disease  
95 incidence has decreased by 90% compared to the outbreak's peak in July 2022<sup>2</sup>, mpox  
96 transmission continues in Africa and Latin America<sup>3</sup>.

97  
98 The recently implemented US mpox vaccination strategy made two smallpox vaccines  
99 available to healthcare workers and individuals 18 years of age and older: ACAM2000 (a  
100 second-generation live-replicating vaccinia strain; Emergent Product Development,  
101 Gaithersburg, MD, USA) and JYNNEOS (a live non-replicating modified Ankara strain of  
102 vaccinia; Bavarian Nordic, Hellerup, Denmark), which is the only vaccine approved for mpox  
103 prevention. Licensed in the US in 2019, JYNNEOS is a third-generation smallpox vaccine  
104 designed to elicit fewer side effects than ACAM2000<sup>4</sup>.

105  
106 To date, robust data demonstrating JYNNEOS protection has only been shown in animal  
107 models<sup>5</sup>. Initial clinical trial data from the UK<sup>6</sup> and the US<sup>7</sup> demonstrated that JYNNEOS efficacy  
108 in humans could reach 78% and 87%, respectively, although these studies did not assess how  
109 the efficacy data could be impacted by behavioral differences between the vaccinated and  
110 unvaccinated individuals. However, while the immunogenicity of the ACAM2000 vaccine has  
111 been investigated<sup>8,9</sup>, little is known about how JYNNEOS induces immune protection in  
112 humans<sup>10,11</sup>.

113  
114 Human smallpox vaccination responses are highly mediated by antibodies<sup>12-16</sup> that can remain  
115 elevated for years<sup>15,17-22</sup>. However, despite this prolonged smallpox protection, the high  
116 frequency of conserved antigens shared between smallpox and mpox<sup>13,14,23</sup>, and the fact that  
117 vaccinia-induced antibodies protect non-human primates from mpox infection<sup>24</sup>, vaccinia  
118 (smallpox) vaccination does not provide complete protection of mpox symptoms in  
119 humans<sup>14,25</sup>. This suggests that mpox immunity might be driven by mpox-specific antigens or  
120 that protection is not strongly antibody-mediated. Finally, it is unclear how JYNNEOS shapes  
121 the human antibody repertoire or how efficiently the antibodies of vaccinated or convalescent  
122 participants neutralize the current mpox outbreak strains.

123  
124 Given the prolonged antibody responses of older smallpox vaccines and high sequence  
125 homology among common OPXVs<sup>4,26</sup>, JYNNEOS was expected to elicit neutralizing immune  
126 responses against the 2022 outbreak strain. However, initial data suggest low humoral  
127 immunogenicity and low virus neutralization potential<sup>11</sup>. Furthermore, no information is  
128 available on how the vaccine alters the antibody repertoire at the immunoglobulin gene level

129 to enable rapid production of antibody-producing B cells targeting mpox epitopes upon future  
130 encounters. Thus, the characterization of JYNNEOS-induced antibodies is imperative.

131  
132 Here, we have examined the human antibody repertoire induced by JYNNEOS in US adult  
133 vaccinees at the single B cell and serum levels. This is the first report of a single-cell human  
134 antibody repertoire induced by mpox vaccination and the first systematic examination of T cell  
135 activation after JYNNEOS vaccination. Importantly, we demonstrate that JYNNEOS immunity  
136 may be primarily T cell-mediated, with minimal activation of humoral immunity.

137

## 138 **Methods**

139

### 140 *Participant demographic and sample collection*

141 The study protocols for clinical specimen collection from convalescent and post-  
142 vaccination individuals by the Personalized Virology Initiative were reviewed and approved  
143 by the Mount Sinai Hospital Institutional Review Board (IRB-16-16772, IRB-16-00791). All  
144 participants provided written informed consent before specimens and clinical information  
145 were collected. Permissions to store and share biospecimen were also obtained from all  
146 participants. All specimens were coded before processing and analysis. Whole blood was  
147 collected through venipuncture into serum separator tubes and  
148 ethylenediaminetetraacetic acid tubes. Serum and plasma were stored at  $-80^{\circ}\text{C}$  until  
149 analysis. Peripheral blood mononuclear cell (PBMC) isolation was performed by density  
150 gradient centrifugation using SepMate tubes (STEMCELL Technologies, Cambridge, MA,  
151 USA). Samples were cryo-preserved in liquid nitrogen until analysis.

152

153 Samples were collected from 16 participants. Ten were vaccinated with JYNNEOS and six  
154 were diagnosed with mpox infection (**Table 1**). Blood samples were collected from seven  
155 vaccinees before vaccination to serve as a baseline. Vaccinee samples were collected on  
156 average 35 days post-dose one (range: 6-60 days) and 13 days post-dose two (range: 7-  
157 40 days). Mpox convalescent samples were collected at an average of 55 days post-  
158 infection (range: 20-102 days; **Table 1**).

159

160

161

162

163

164

165

166

167

168

169 **Table 1. Subject demographics and immunization routes of JYNNEOS vaccine recipients and**  
 170 **mplex-convalescent participants**

Subject ID	Sex	Age	Race	Orthopoxviral exposure	IR-1 <sup>st</sup> Dose	IR-2 <sup>nd</sup> Dose
<b>V1</b>	M	21-30	C	JYNNEOS	Subcutaneous	Intradermal
<b>V2</b>	M	31-40	C	JYNNEOS	Subcutaneous	Intradermal
<b>V3</b>	M	41-50	C	JYNNEOS	Subcutaneous	-
<b>V4</b>	M	41-50	H	JYNNEOS	Subcutaneous	Subcutaneous
<b>V5</b>	M	31-40	H	JYNNEOS	Subcutaneous	Intradermal
<b>V6</b>	M	41-50	C	JYNNEOS	Subcutaneous	Intradermal
<b>V7</b>	M	31-40	C	JYNNEOS	Subcutaneous	Intradermal
<b>V8</b>	M	41-50	C	JYNNEOS	Subcutaneous	Intradermal
<b>V9</b>	M	41-50	C	JYNNEOS	Intradermal	-
<b>V10</b>	M	31-40	C	JYNNEOS	Subcutaneous	Subcutaneous
<b>C1</b>	M	41-50	AA	Mpox Infection	-	-
<b>C2</b>	F	31-40	AA	Mpox Infection	-	-
<b>C3</b>	M	31-40	C	Mpox Infection	-	-
<b>C4</b>	M	41-50	C	Mpox Infection	-	-
<b>C5</b>	M	31-40	C	Mpox Infection	-	-
<b>C6</b>	M	51-60	E	Mpox Infection	-	-

171 IR= immunization route. C = Caucasian, H = Hispanic, AA= African American E=Ecuadorian.

172  
173

174 *Flow cytometry and cell sorting*

175 Cryopreserved PBMCs from JYNNEOS recipients were thawed in Roswell Park Memorial  
 176 Institute RPMI 1640 Medium w/ L-glutamine and 25 mM HEPES (Corning, Corning, NY,  
 177 USA, 10-041-CV) supplemented with 10% fetal bovine serum (FBS) and 500 U of  
 178 Benzoylarginine Nucleoside (MilliporeSigma, Burlington, MA, USA, 71206-25KUN) at 37°C.  
 179 Cells were washed with cold FACS buffer (phosphate-buffered saline (PBS; Thermo Fisher  
 180 Scientific, Waltham, MA, USA, 10010023) with 2% FBS), resuspended for counting, then  
 181 aliquoted into 96-well plates (Corning 96-well Clear Polystyrene Microplates, Corning,  
 182 #3788) and stained for plasmablasts defined as (Dump- (CD3, CD14, CD16, CD56), CD19+  
 183 IgD-, CD20-CD38hi, and CD71+) (**Figure S1**) in BD Horizon Brilliant Stain Buffer (BD  
 184 Biosciences, San Jose, CA, USA, 566349) for 30 min at 4°C. Cells were then washed with  
 185 cold FACS buffer and dead cells were detected using the LIVE/DEAD Fixable Blue Dead  
 186 Cell Stain Kit (Thermo Fisher Scientific, L34962) in Dulbecco's PBS with calcium and  
 187 magnesium (Thermo Fisher Scientific, 14040133) at 4°C for 15 min. Cells were washed and  
 188 resuspended in FACS buffer, then sorted into Eppendorf™ DNA LoBind Microcentrifuge  
 189 Tubes (Thermo Fisher Scientific, 022431021) containing 12 µL of PBS with 0.05% bovine  
 190 serum albumin (BSA) and directly loaded into a 10x Genomics Chromium Next GEM Chip  
 191 K (10x Genomics, Pleasanton, CA, USA, PN-2000182) for analysis.

192  
193  
194  
195  
196

197 **Table 2. Antibodies used for flow cytometry and cell sorting**

198

Antibody	Vendor	Dilution
IgD BUV737 (IA6-2)	BD Horizon	1:200
CD20 BV510 (2H7)	BioLegend	1:100
CD38 BV650 (HB-7)	BioLegend	1:200
CD27 BB515 (M-T271)	BD Horizon	1:200
CD3 PerCP (SK7)	BioLegend	1:100
CD14 PerCP (63D3)	BioLegend	1:200
CD16 PerCP (3G8)	BioLegend	1:200
CD56 PerCP (HCD56)	BioLegend	1:200
CD71 PE/Dazzel 594 (CY1G4)	BioLegend	1:200

199

200 *Single-cell RNA sequencing library preparation*

201 Sorted plasmablasts were processed using 10x Genomics kits (Next GEM Single Cell 5'  
202 GEM Kit v2 Dual Index (PN-1000244), Chromium Next GEM Chip K Single Cell Kit (PN-  
203 1000286), Chromium Single Cell Human BCR Amplification Kit (PN-1000253), Library  
204 Construction kit (PN-1000190), and Dual Index Kit TT Set A (PN-1000215)) according to  
205 the manufacturer's protocols. We used cDNA to prepare B cell receptor (BCR) and 5' gene  
206 expression libraries. All quantifications were performed on a TapeStation 2200 (Agilent,  
207 Santa Clara, CA, USA). Libraries were sequenced on a NovaSeq 6000 at sequencing read  
208 depths of 5,000 and 50,000 for VDJ and gene expression libraries, respectively.

209

210 *Bioinformatic analyses of BCR sequencing*

211 Raw sequencing reads were processed with Cell Ranger 7.0.1 (10x Genomics) and  
212 reference VDJ germline sequences were retrieved from IMGT (2022-12-28). The  
213 assembled contigs were analyzed with the nextflow pipeline nf-core/airflow ([https://nf-](https://nf-co.re/airflow)  
214 [co.re/airflow](https://nf-co.re/airflow) commit  
215 072a40bf6d8352f9dc33456d69b9156ffb2906bd), using an Immcantation  
216 (<http://www.immcantation.org>) docker container (build  
217 515029fbe323e7479190f14ebcf188ec76f6d90cfea7ce3a89d17f24ee7ded35, available  
218 at  
219 DockerHub) and the same reference germlines used with Cell Ranger. The pipeline  
220 performs the following processing steps: gene assignment with IgBLAST (version 1.20.0),  
221 quality filtering (retaining sequences with concordant loci in the v\_call and locus fields  
222 identified by IgBLAST, with a sequence\_alignment with a maximum of 10% Ns and a length  
223 of at least 200 informative nucleotides (not -, ., or N)), removal of non-productive  
224 sequences, removal of sequences with junction lengths that are not multiples of 3, single  
225 cell-specific quality filters (keeping cells with one heavy chain, removing sequences with  
226 the same cell\_id, and sequence in different samples), and clustering of clonally related  
227 sequences. To identify clones, we used the hierarchical clustering method implemented  
228 in SCOper<sup>27</sup> with a nucleotide Hamming distance threshold of 0.17. Differences in gene  
229 and isotype usage and mutation frequency were determined by *t*-test.

230

231 *Bioinformatic analyses of gene expression data*

232 We used the Cell Ranger<sup>28</sup> pipeline and the Seurat R<sup>29</sup> package for single-cell  
233 transcriptome analysis. The steps were as follows: fastq generation and demultiplexing,  
234 quality control at the library and individual cell levels, transcript quantification and  
235 normalization, dimensionality reduction, cell clustering, differential gene expression  
236 analysis, and data visualization. We ran the Cell Ranger pipeline to obtain gene expression  
237 count matrices from the raw sequencing data using standard parameters and the expected  
238 number of cells for each sample set as the number of sorted cells (using the "--expect-cells"  
239 parameter). The gene expression data and metadata for each cell were used to create  
240 Seurat objects. We removed cell barcodes with < 200 or > 2,500 genes detected  
241 (nFeature\_RNA), as well as those with > 10% mitochondrial content. The number of cell  
242 barcodes was then downsampled to match the sample with the least barcodes. We  
243 normalized each subsample using regularized negative binomial regression as provided  
244 by the SCTransform function, resulting in a list of normalized Seurat objects. The top 3,000  
245 most variable genes across each comparison were selected using the  
246 SelectIntegrationFeatures function and used for sample integration using the  
247 PrepSCTIntegration, FindIntegrationAnchors, and IntegrateData functions. We reduced  
248 the dimensionality of the data using the uniform manifold approximation and projection  
249 (UMAP) technique on the 30 largest principal components computed by principal  
250 component analysis with the RunUMAP function and used this data structure to find  
251 neighbours and cluster cell groups using the FindNeighbors and FindCluster functions,  
252 respectively. We computed the differentially expressed genes in each group using the  
253 Wilcoxon rank-sum test, followed by Benjamini-Hochberg false discovery rate (FDR)  
254 correction. Genes with FDR < 0.01 and log fold change (FC) > 0.2 were considered  
255 differentially expressed in an experimental group. We observed a bimodal distribution in  
256 the total reads mapping to genes encoding ribosomal proteins, and a considerable  
257 fraction of these genes were differentially expressed. For this reason, we repeated the  
258 pipeline described above with the 103 ribosomal genes removed from the count matrices  
259 before sample normalization.

260

261 *Recombinant proteins*

262 To express proteins derived from the Zaire-96-I-16 strain of mpox, cDNAs encoding  
263 residues 1-275 of E8L (GenBank: 72551515), 22-146 of A30L (GenBank: 72551549), 1-110  
264 of A29L (GenBank: 72551548), and 58-181 of A35R (GenBank: 72551555) were  
265 synthesized along with a GGS GGGS linker and a 10×His tag and cloned into the  
266 mammalian expression vector pcDNA3.4. These expression vectors were transiently  
267 transfected into HEK293F cells with polyethylenimine. Proteins were purified from filtered  
268 cell supernatants with Ni-NTA resin before additional purification by size-exclusion  
269 chromatography using a Superdex 200 Increase 10/300 GX column (GE Healthcare,  
270 Boston, MA, USA) in PBS (pH 7.4) containing 0.005% Tween 80 and 10% trehalose. These

271 recombinant mpox proteins are available for purchase from ACROBiosystems (Newark,  
272 DE, USA; E8L, E8L-M52H3; A30L, A3L-M5243; A29L, A2L-M52H3; A35R, A3R-M52H3).

273  
274 Recombinant vaccinia virus (VACV) proteins B5 (40900-V08H), L1R (40903-V07H),  
275 B18R/B19R (40020-V08B), A27L (40891-V07E), and A33R (40896-V07E), from the  
276 Copenhagen strain of VACV, were purchased from Sino Biological (Beijing, China).

#### 277 278 *Enzyme-linked immunosorbent assays (ELISAs)*

279 Serum antibody titers were quantified via ELISA using the recombinant proteins listed  
280 above and lysates derived from cells infected with the current US outbreak strain of mpox.  
281 In addition, lysates of mpox infected HRT-18 cells were also used to probe polyclonal  
282 antibody responses. Following lysis in 1% SDS solution and freezing at -80C, the SDS was  
283 removed using the SDS-out SDS Precipitation Kit (Thermo Fisher Scientific, 20308)  
284 according to the manufacturer's instructions. ELISAs were performed in MultiScreen® 96-  
285 well ELISA high binding plates (Millipore, MSEHNF40). Plates were coated with 50 µL of 2  
286 µg/mL recombinant protein, except for A30L and E8L, which were coated at 1 µg/mL.  
287 Inactivated SDS-free mpox cell lysates were coated at 5 µg/mL. All plates were coated for  
288 1 hour in a 37°C incubator, then blocked for 1 hour at room temperature in PBS  
289 supplemented with 0.1% Tween 20 (PBST; Thermo Fisher Scientific ref. J61419.K3) and 3%  
290 milk powder (AmericanBio, Canton, MA, USA, AB1010901000). Heat-inactivated serum  
291 samples were diluted 1:40 in PBST containing 1% milk powder and then serially diluted  
292 1:3. The blocking solution was removed from the plates and the serum dilutions were  
293 added. After incubation for 2 hours at room temperature, plates were washed three times  
294 with PBST using a BioTek 405 TS microplate washer (Agilent). After washing, 100 µL of Anti-  
295 Human IgG (Fab specific)–Peroxidase secondary antibody (produced in goat; Sigma-  
296 Aldrich, St. Louis, MO, USA, A0293, RRID: AB\_257875) diluted 1:3,000 in PBST with 1%  
297 milk powder was added. After a 1-hour incubation at room temperature, the plates were  
298 washed three times with PBST and 100 µL SIGMAFAST™ OPD (Sigma-Aldrich, P9187) was  
299 added. After a 10-minute incubation at room temperature in the dark, the reaction was  
300 stopped by adding 50 µL of 3 M hydrochloric acid (Thermo Fisher Scientific, S25856) to  
301 each well. The optical density at 490 nm of each plate was measured using a BioTek  
302 Synergy H1 Multi-Mode Reader (Agilent). The area under the curve (AUC) was then  
303 calculated for each plate and plotted using GraphPad Prism 9 software (GraphPad  
304 Software, San Diego, CA, USA).

#### 305 306 307 *Combined activation-induced marker (AIM)/intracellular cytokine staining (ICS) assays to* 308 *detect antigen-specific T cell responses*

309 We investigated orthopox-specific T cell responses using previously described peptide  
310 pools<sup>30</sup>. The OPXV peptides were based on experimentally defined CD4 and CD8  
311 epitopes from IEDB ([www.IEDB.org](http://www.IEDB.org)). Peptides were synthesized as crude materials (TC



312 Peptide Lab, San Diego, CA, USA), pooled into OPXV CD4 and OPXV CD8 mega pools,  
313 and sequentially lyophilized<sup>30</sup>.

314 To assess OPXV-specific T cell responses, PBMCs were cultured with the OPXV-specific  
315 peptide mega pools (1 µg/mL). An equimolar amount of dimethyl sulfoxide (DMSO) was  
316 added to duplicate wells as a negative control, and phytohemagglutinin-L (1 µg/mL,  
317 Millipore, Saint Louis, MO, USA 431784) was used as a positive control. Stimulated cells  
318 were incubated with CD40 (1:133, Miltenyi Biotec, Gaithersburg, MD, USA, 130-094-133)  
319 and CXCR5 BV650 (1:100, BD Biosciences, 740528) antibodies at 37°C in 5% CO<sub>2</sub> for 26  
320 hours. During the last 4 hours of incubation, a combination of Golgi-Plug containing  
321 brefeldin A, Golgi-Stop containing monensin (1:1000, both BD Biosciences), and CD137  
322 APC antibodies (1:100, BioLegend, San Diego, CA, USA, 309810) was added. Membrane  
323 surface staining was performed for 30 minutes at 4°C with eBioscience™ Fixable Viability  
324 Dye eFluor™ 506 (1:1,000, Thermo Fisher Scientific, 65-0866-14) and the following  
325 antibodies: CD3 BUV805 (1:50, BD Biosciences, 612895), CD8 BUV496 (1:50, BD  
326 Biosciences, 612942), CD4 BUV395 (2:100, BD Biosciences, 564724), CD14 V500 (1:50,  
327 BD Biosciences, 561391), CD19 V500 (1:50, BD Biosciences, 561121), CD69 BV605 (4:100,  
328 BioLegend, 310938), CD137 APC (1:50, BioLegend, 309810), OX40 PE-Cy7 (1:50,  
329 BioLegend, 350012), CXCR5 BV650 (2:100, BD Biosciences, 740528), and CD154 (CD40  
330 Ligand) Monoclonal Antibody (24-31), APC-eFluor™ 780, eBioscience (5:100, Thermo  
331 Fisher Scientific, 47-1548-42). Cells were then fixed with 4% paraformaldehyde (Sigma-  
332 Aldrich), permeabilized with saponin buffer (0.5% saponin (Sigma-Aldrich), 1% BSA, and  
333 0.1% sodium azide), and blocked for 15 minutes with 10% human serum (Gemini Bio-  
334 Products, Sacramento, CA, USA) in saponin buffer. Intracellular staining was performed for  
335 30 minutes at room temperature with the following antibodies: TNFα-PE (1:500, Thermo  
336 Fisher Scientific, 12-7349-82), IFNγ FITC (1:50, Thermo Fisher Scientific, 11-7319-82), IL4  
337 BV711 (1:50, BD Biosciences, 564112), IL10 PE-Dazzle594 (1:100, BioLegend, 506812),  
338 and granzyme B Alexa 700 (1:100, BD Biosciences, 560213). Samples were run on a ZE5  
339 Cell Analyzer (Bio-Rad, Hercules, CA, USA) and were analyzed with FlowJo 10.8.1 (Tree  
340 Star Inc., Ashland, OR, USA). Limit of detection (twice the upper 95% confidence interval  
341 of the geometric mean) and limit of sensitivity (LOS, twice the standard deviation from the  
342 median) calculations were based on the DMSO-only conditions for AIM and ICS.  
343 Responses were considered positive with a stimulation index > 2 and AIM LOS values of  
344 0.02 and 0.04 for CD4 and CD8, respectively. For ICS, a stimulation index > 2 was  
345 considered positive when combined with LOS values of 0.01 for both CD4 and CD8.

346

#### 347 *Role of the funding sources*

348 The study sponsors had no role in the study design; in the collection, analysis, and  
349 interpretation of data; in the writing of the report; or in the decision to submit the paper  
350 for publication.

351

352

## 353 Results

354 B cell activation by immunization leads to their differentiation into short-lived, antibody-  
355 secreting plasmablasts. Single-cell sequencing of plasmablasts obtained 6-9 days after  
356 JYNNEOS vaccination demonstrated that neither one nor two doses significantly increased  
357 the number of variable heavy chain (VH) sequence clonotypes (**Figure S2A, Table S1**) or  
358 their diversity, as defined by three criteria (**Figure 1A**). Two doses did not significantly alter  
359 the frequency of VH mutations (**Figure 1B**), suggesting that at least shortly after each  
360 immunization, JYNNEOS vaccination does not sufficiently engage antigen-mediated  
361 germinal center responses to promote somatic hypermutation. Similarly, the length of  
362 complementarity-determining region 3 (CDR3) in the antibody heavy chain, an indicator of  
363 antigen binding specificity after vaccination<sup>31,32</sup>, was unaltered after JYNNEOS  
364 immunization (**Figure 1C**). In pre-vaccinated (unvaccinated, and uninfected) participants,  
365 the antibody repertoire of naïve B cells mainly comprised IgM sequences (**Figure 1D**), as  
366 recently demonstrated by Lanzavecchia and his group<sup>33</sup>. Compared to pre-vaccination,  
367 IgA levels were increased after one dose, which was accompanied by decreased IgM levels  
368 (**Figure 1D**). Two doses of JYNNEOS did not alter immunoglobulin isotype frequencies  
369 compared to pre-vaccination (**Figure 1D**). Similarly, one or two doses of JYNNEOS did not  
370 affect heavy chain mutation frequencies in the IgG, IgA, and IgM isotypes (**Figure 1E,**  
371 **Figure S2B**). Compared to pre-vaccination, one or two doses of JYNNEOS did not  
372 significantly alter immunoglobulin heavy chain variable (IGHV) gene families (**Figure S2C**).  
373 Although usage of *IGHV1-2*, *IGHV1-46*, *GHV4-39*, and *IGHV4-59* seemed slightly increased  
374 in two participants after the second dose (**Figure 2**), these increases were not significant.  
375 Since no significant changes in plasmablast antibody gene expression were observed after  
376 one or two doses, we next expanded our search to characterize global gene expression  
377 patterns. After quality control (**Figure S4 and S5**), we saw that in pre-vaccination CD19+  
378 B cells, we identified transcripts commonly expressed in B cells, such as *BANK1*, *BACH2*,  
379 and *ARHGAP24*<sup>34-36</sup> (**Figure S6**). Given the high levels of ribosomal proteins expressed in  
380 total B cells, we also analyzed the dataset after removing these reads; however, the gene  
381 expression profiles identified differentially expressed B cell-related genes remained  
382 comparable (**Figure S7**). Compared to their baselines, plasmablasts obtained from paired  
383 subjects post-dose one expressed high levels of *CD74* (**Figure S6**), which is expressed in  
384 antigen-experienced cells<sup>37</sup> and was part of a gene cluster (cluster 1) that expanded after  
385 vaccination (**Figure S6**). This change was expected since we analyzed plasmablasts, which  
386 are more differentiated than the total B cells taken pre-vaccination. However, and more  
387 importantly, the most differentially expressed genes after dose one and dose two were  
388 unchanged (**Figure S6**), suggesting that a second dose of JYNNEOS did not significantly  
389 alter plasmablast gene expression.

390  
391 As plasmablast responses seemed unaffected at the single-cell level, we also analyzed the  
392 antibodies they secrete into circulation. Since plasmablasts are short-lived, early  
393 responders that peak 6-9 days post-vaccine, we were also curious to evaluate vaccine

394 responses up to 2 months post-immunization. We quantified serum IgG responses after  
395 immunization or infection. Initially, we expressed the mpox proteins A29L, A35R, A30L and  
396 E8L (strain Zaire-96-I-16), all known antibody targets<sup>38</sup> that can induce B cell  
397 immunogenicity<sup>39-44</sup>. IgG responses to A29L and A35R proteins were increased only after  
398 infection (**Figure 3A-D**) and were undetectable or present at very low levels in the serum  
399 of vaccinees shortly after or up to 60 days after the first or second doses (**Figure S8**). A30L  
400 was the only protein we analyzed that demonstrated JYNNEOS induced significant IgG  
401 response after two doses, with IgG levels comparable to those observed during  
402 convalescence. Responses to the E8L protein were detected in sera collected 18-60 days  
403 after one or two doses but not shortly after immunization (**Figure S8A-H**).

404  
405 As the high conservation of OPXVs results in the production of cross-reactive antibodies  
406 upon vaccination<sup>13</sup>, we next sought to assess serum antibody responses to vaccinia  
407 proteins previously identified as targets of human neutralizing antibodies<sup>38</sup>. One or two  
408 doses of JYNNEOS did not elicit robust IgG responses to the four proteins we tested (A27L,  
409 L1R, B18R and A33R). Infection, however, generated robust serum IgG responses against  
410 A33R and A27L (**Figure 3E-F**). Only three convalescent individuals and none of the  
411 vaccinees had IgGs targeting B18R (**Figure 3G**). Mpox infection did not generate  
412 antibodies against L1R, and only one subject was responsive to it after vaccination (**Figure**  
413 **3H**). As most convalescent subjects in this study also had human immunodeficiency virus  
414 (HIV), and HIV+ individuals are commonly (average of 18%)<sup>45</sup> infected with the OPXV  
415 *Molluscum contagiosum*<sup>46,47</sup>, we sought to confirm whether their convalescent responses  
416 were mpox-specific or cross-reactive. We therefore tested the sera of HIV+ and  
417 HIV+/mpox+ subjects with the mpox protein A29L, which was very immunogenic in  
418 convalescents. Anti-A29L levels in co-infected subjects were found to be above the limit of  
419 detection compared with those with HIV only (**Figure S8I**). This indicates that the  
420 responses raised were due to mpox infection alone.

421 Finally, we isolated mpox virus from an infected lesion derived from an infected individual  
422 during the 2022 outbreak and developed an ELISA to assess IgG responses to lysates from  
423 mpox-infected cells. The serum of vaccinees receiving one or two doses of JYNNEOS did  
424 not bind the mpox proteins in the lysate, while 4/6 convalescent participants elicited strong  
425 antibody responses (**Figure 3I**).


426  
427 Taken together, our results demonstrate that—unlike previous generations of smallpox  
428 vaccines—JYNNEOS does not induce a strong humoral response to OPXVs in humans.  
429 Human clinical trials indicate protection against mpox<sup>6,7,48,49</sup>. Therefore, we next  
430 investigated how JYNNEOS vaccination induces T cell immunity in humans compared to  
431 mpox infection. We measured the antigen-specific CD4+ and CD8+ T cell responses to  
432 JYNNEOS immunization or mpox infection using a previously reported<sup>30</sup> pool of VACV  
433 peptides (**Figure 4**). T cell responses were measured using a combined AIM/ICS assay  
434 (see **Figure S9A** for the gating strategy). CD4+ T cells showed pre-existing immunity

435 before vaccination, with a higher frequency of positivity and increased reactivity after two  
436 doses and a response comparable to post-mpox infected samples (**Figure 4A-B**).  
437 Circulating T follicular helper (cTFH) cell levels were significantly increased post-  
438 vaccination but not after mpox infection (**Figure 4C**). CD8+ T cells displayed little to no  
439 evidence of pre-existing immunity, but robustly increased in response to two doses of  
440 JYNNEOS compared to baseline and after mpox infection ( $p < 0.05$ ). Although they lacked  
441 pre-immunity, CD8+ T cell responses presented similar FC increases to CD4+ T cells in  
442 response to vaccination (**Figure 4D-E**). The T cell responses involved the production of  
443 multiple cytokines, revealing a trend toward increased polyfunctionality post-vaccination  
444 or -infection (**Figure 4F**), including the presence of mixed T helper type (Th)1/(Th)2 cell  
445 phenotypes (**Figure S10**). Finally, no significant correlations were observed between the  
446 T cell and antibody responses (**Figure S11**) and the lower cTFH responses observed in  
447 convalescent samples were not correlated with the differences in the time following  
448 exposure between infected and vaccinated participants (**Figure S11**). Antibody responses  
449 to vaccination were also not associated with the day post-immunization, suggesting that  
450 although these samples were collected closer to exposure than the convalescent samples  
451 (**Figure S11**), this difference is likely not responsible for the superior antibody responses  
452 mounted against infection.

453

454

455



**Figure 1. Antibody repertoires of single B cells after one and two doses of JYNNEOS**

(A) Heavy chain variable (VH) sequence diversity was measured using three different parameters. Plasmablasts were collected 6-9 days after one or two doses of JYNNEOS. Total B cells (CD19+) from the same participants were collected before immunization and sorted for single-cell sequencing.

(B) Frequency of VH mutations.

(C) CDR3 amino acid (AA) lengths.

(D) Frequencies of immunoglobulin isotypes.

(E) Frequencies of heavy chain gene mutations according to immunoglobulin isotype.


Statistical significance was evaluated with *t*-tests. Participants are identified by unique symbols.

456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468



469  
470  
471  
472


**Figure 2. Variable gene usage in pre-vaccine B cells and plasmablasts after one or two doses of JYNNEOS**  
IGHV genes of the *IGHV-1-6* families are shown. Statistical significance was evaluated by *t*-test



473  
 474  
 475  
 476  
 477  
 478  
 479

**Figure 3. Serum antibody responses to recombinant mpox proteins and lysates from mpox-infected cells**  
**(A-D)** Serum IgG responses to recombinant mpox proteins A29L (A), A35R (B), E8L (C), and A30L (D) at baseline and 18–60 days post-immunizations or 45–102 days post-infection. AUC, area under the curve. The donut graphs illustrate the proportion of samples in each group that were reactive to the recombinant proteins. Positivity was defined based on limit of detection (mean+ 3x SD of negative controls)

480 **(E-H) Serum IgG responses to recombinant vaccinia proteins A27L (E), L1R (F), B18R (G) and A33R (H) at**  
 481 **baseline and post-immunizations or -infection.** The day ranges are the same as A-D.  
 482 **(I) Serum IgG responses of vaccinated and convalescent participants to a lysate from mpox-infected cells.**  
 483 Dashed lines represent the limit of detection (defined as the mean + three standard deviations).  
 484 Comparisons were performed using the Kruskal-Wallis test followed by Dunn's multiple comparisons test (\* $p <$   
 485  $0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ). **Supplementary Figure 8** shows additional IgG data from an earlier time point post-  
 486 immunization.  
 487



488 **Figure 4. Human CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses to JYNNEOS immunization or mpox infection**  
 489 **(A-B)** CD4 T cell responses to the OPXV peptide pool 9-114 days after vaccination and the magnitudes of their  
 490 AIM (A) or ICS (B) responses pre- and post-vaccination or 20-130 days post-mpox infection. FC, fold change.  
 491 **(C)** OPXV-specific CD4 cTFH cell responses to the OPXV peptide pool after vaccination and AIM magnitudes pre-  
 492 and post-vaccination or post-mpox infection.  
 493 **(D-E)** CD8 T cell responses to the OPXV peptide pool after vaccination and the magnitudes of their AIM (D) or ICS  
 494 (E) responses pre- and post-vaccination or post-mpox infection.  
 495 **(F)** Functionality of OPXV-specific CD4<sup>+</sup> CD4 and CD69<sup>+</sup> CD8 cytokine responses pre- and post-vaccination or  
 496 post-mpox infection.  
 497 Dashed lines represent the LOS. The significance of the FC was assessed by Wilcoxon signed rank test compared  
 498 to a hypothetical median of 1. Baseline and post-dose two values were compared by one-tailed Wilcoxon test,  
 499 baseline and convalescent samples were compared by one-tailed Mann-Whitney test, and dose two and  
 500 convalescent were compared by two-tailed Mann-Whitney test. *P*-values are listed above the data points. The  
 501 donut graphs represents the frequency of positivity based on the limit of detection.  
 502 **Supplementary Figure 9** shows the gating strategy for the T cell assay and the individual cytokine responses.  
 503  
 504  
 505  
 506  
 507  
 508



## 509 Discussion

510  
511 Human OPXV vaccines have an extraordinary history of successful protection from illness.  
512 The first-generation Dryvax vaccine prevented smallpox but caused severe side effects,  
513 leading to the development of second- (ACAM2000) and third- (JYNNEOS) generation  
514 vaccines. JYNNEOS is safe, immunogenic, and protective against smallpox in humans<sup>50-52</sup>.  
515 Consequently, it was authorized by the US Food and Drug Administration (FDA) for mpox  
516 prevention during the 2022 global outbreak. However, the immunogenicity and efficacy  
517 of third-generation vaccines designed to prevent smallpox have not been thoroughly  
518 evaluated, including their functional activities and, more importantly, their mechanism(s)  
519 of protection against mpox. To gain insight into JYNNEOS' immunogenicity and mpox  
520 protection, we evaluated various metrics of adaptive responses in US adults after one and  
521 two JYNNEOS vaccine doses. These adults were all born after 1974 and were not exposed  
522 to smallpox or smallpox vaccines (as the US ended routine vaccinations in 1972). A strength  
523 of this study is that we used paired samples to evaluate B cell responses at the single cell  
524 and serum levels, combined with cellular antigen-specific T cell analyses.

525 Several lines of evidence in this study suggest that JYNNEOS protection is not primarily  
526 mediated by B cells in humans: the diversity, mutation levels, and CDR3 lengths of B cell  
527 heavy chain sequences revealed no significant changes after two doses. Vaccines  
528 mediated by antibodies usually induce changes in antibody genes that increase their  
529 binding and functional activity<sup>43,53-57</sup>. VH gene usage also usually changes after human  
530 immunization<sup>58-60</sup> but did not significantly increase or decrease in the six gene families we  
531 analyzed.

532 Additionally, gene expression data revealed no significant changes after vaccination,  
533 although only analyzed in one individual at each time point (same subject for pre-  
534 vaccination and post-dose 1). A recent study mapping the expression patterns of single  
535 plasmablasts from > 800 adults in response to 13 vaccines<sup>61</sup> confirmed that there is no  
536 single universal marker of vaccination in human plasmablasts. Our dimensionality  
537 reduction analyses by UMAP revealed that genes related to B cell activation, such as CD74,  
538 were increased in plasmablasts after one dose compared to in B cells in the pre-vaccination  
539 samples, as expected. However, consistent with our BCR sequencing results, we did not  
540 observe any gene expression changes between post-dose one and two, confirming that  
541 JYNNEOS did not significantly impact human B cell responses.

542 OPXV-elicited antibodies have significantly better cross-neutralizing potential compared  
543 to those targeting other viruses, such as HIV and influenza virus<sup>26</sup>, due to the a) high  
544 sequence homology between the surface proteins of VACV, mpox virus, smallpox virus,  
545 and cowpox virus (89-100% similarity) and b) the broad neutralization effects of OPXV  
546 antibodies, which can target multiple viral surface proteins concomitantly<sup>62-64</sup>. Therefore,

547 we evaluated antibody secretion by memory B cells, with the idea that if serum antibodies  
548 offered direct protection against the virus in circulation, we could combine this knowledge  
549 with the single-cell data to better characterize humoral responses to JYNNEOS in humans.  
550

551 However, serum IgG antibodies in post-vaccination samples did not bind any of the  
552 recombinant mpox proteins. Since cross-reactive antibodies are expected in response to  
553 OPXV exposure<sup>38</sup>, we tested the same sera against vaccinia proteins. Again, neither one  
554 nor two doses of JYNNEOS produced antibodies that could bind the vaccinia proteins,  
555 suggesting that the JYNNEOS vaccine cannot elicit strong humoral responses post-  
556 vaccination. The strong IgG responses to the same OPXV proteins by sera from subjects  
557 20-102 days post-mpox infection clearly illustrate the vaccine's limited antibody response.  
558 Convalescent participants presented a range of IgG responses against the proteins we  
559 analyzed, consistent with studies showing that different viral loads and clinical  
560 determinants dictate the response to mpox virus infection<sup>65</sup>. A recent ELISA-based study  
561 reported vaccine-specific IgG peaks in the serum of JYNNEOS-vaccinated participants  
562 after 42 days<sup>66</sup>. In addition, a recent study reported lower A35R- and H3L-specific titers in  
563 antigen-specific IgG tests compared to tests against the whole sera of convalescent  
564 participants, suggesting that IgMs might be among the immunoglobulins responding up  
565 to 50 days post-viral exposure (in that case, *via* infection)<sup>40</sup>. The reference strains of VACV  
566 and mpox virus share > 90% identity. The 2022 mpox virus strain has unique mutations  
567 compared to the reference strain, including A35R mutations at positions A67 (to L) and  
568 A88 (to V), which were exclusively found during the 2022 outbreak<sup>38</sup>. Whether these  
569 mutations can impact serum IgG binding to the recombinant mpox virus protein remains  
570 to be investigated. We found a positive correlation between JYNNEOS-elicited antibodies  
571 against the A35R and A33R proteins, suggesting that the common sequences these  
572 orthologs share induce comparable antibody responses to the vaccine. Finally, we  
573 confirmed the A35R protein as a serum marker of human mpox virus infection<sup>40</sup>, given the  
574 total absence of AS35R-IgG in the serum after vaccination.

575  
576 Our data establish that the B cell immunogenicity of JYNNEOS vaccination is low up to 2  
577 months post-vaccination. Thus, what mediates JYNNEOS' protective effects in humans if  
578 not B cells and antibodies?

579  
580 Immunity to many pathogens, including viruses, can be highly dependent on T cells<sup>67,68</sup>.  
581 To test if JYNNEOS induces T cell-dependent immune protection, we tested T cell  
582 responses against peptide pools designed based on VACV antigens, although in a limited  
583 set of samples due to lack of cell availability. Two doses of JYNNEOS elicited substantial  
584 CD8+, CD4+, and cTFH T cell responses with similar fold increases. We also noted the  
585 presence of pre-existing CD4+, but not CD8+, T cell immunity, as previously reported for  
586 Dryvax vaccination<sup>30</sup>. JYNNEOS vaccination and mpox infection produced similar  
587 magnitudes of reactivity for CD4+ and CD8+ T cells; however, after infection, the

588 frequency of the T cell response trended lower after infection than after vaccination,  
589 consistent with a previous study showing that mpox infection specifically decreased  
590 antiviral-specific T cell reactivity<sup>69</sup>. Intriguingly, we also observed significantly lower cTFH  
591 T cell induction after infection versus vaccination. Finally, the quality of the vaccinia-specific  
592 T cells indicates the presence of a Th1/Th2 mixed phenotype, as previously reported for  
593 smallpox vaccination<sup>70</sup> but not, until now, in the context of mpox virus infection. Our study  
594 was not designed to address particularities across different vaccinia virus-based  
595 vaccination platforms. Accordingly, whether the reduced antibody activity seen in  
596 response to JYNNEOS is related to inferior neutralization activity compared to Dryvax<sup>71</sup>  
597 needs further assessment. Additionally, although previous reports demonstrated that the  
598 antigens recognized by T cells are highly correlated with those recognized by antibody  
599 responses<sup>42</sup>, JYNNEOS' T cell-mediated protection might be due to epitopes elicited only  
600 in response to vaccinia-based vaccines and not mpox infection as the two proteomes share  
601 61-67% of sequence conservation<sup>30</sup>. Alternatively, genes lost in the MVA versus Dryvax<sup>72</sup>  
602 may account for a fraction of T cell responses that are not induced in JYNNEOS vaccination.  
603 Future studies should address, more in-depth, the antigens recognized by T cell  
604 responses.

605  
606 This study has some limitations. We did not assess the roles of other immune cells (e.g.,  
607 innate immune cells) in mediating mpox protection. The gene expression data was  
608 assessed using one subject per time point; however, in our opinion, this does not reduce  
609 the importance of the data, which was used for descriptive purposes, with no statistical  
610 comparisons performed between the different groups. Our study did not comprise virus  
611 neutralization assays, and thus, we cannot assess whether the low humoral response would  
612 be associated with low viral neutralization.<sup>713072</sup>

613 Taken together, our results indicate that JYNNEOS elicits low B cell and antibody  
614 responses in humans. However, it induces a robust T cell response that can recognize  
615 mpox virus and VACV peptides. These data provide insights into the protective  
616 mechanisms of a third-generation OPXV vaccine, which can be used to inform vaccine  
617 design and clinical data assessment during future OPXV outbreaks.

618  
619

## 620 **Author contributions**

621 CHC and VS conceptualized the study. HC, NB, JC, and AT performed the experiments.  
622 JC, WR, and LQ designed, expressed, and isolated recombinant mpox proteins. NB, JC,  
623 HC, AT, and CHC analyzed the data. FPL and SM performed bioinformatic analyses. CHC,  
624 SC, and VS funded the study. CHC, VS, SC, AG, AS, and FK supervised experiments. VS  
625 supervised the clinical study. CHC wrote the manuscript draft. All authors interpreted the  
626 data, provided critical input, and revised the manuscript.

627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666

### **Data Sharing**

Additional deidentified data may be made available to investigators whose proposed use of the data has been approved by the Icahn School of Medicine Ethics Review Board upon request to the corresponding authors.

### **Declaration of Interests**

Florian Krammer has been consulting for Curevac, Seqirus and Merck and is currently consulting for Pfizer, Third Rock Ventures, Avimex and GSK. He is named on several patents regarding influenza virus and SARS-CoV-2 virus vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of these technologies have been licensed to commercial entities and Dr. Krammer is receiving royalties from these entities. Dr. Krammer is also an advisory board member of Castlevax, a spin-off company formed by the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory has received funding for research projects from Pfizer, GSK and Dynavax and three of Dr. Krammer’s mentees have recently joined Moderna. The authors declare no competing interests. L.J.I. has filed for patent protection for various aspects of T cell epitope and vaccine design work. Alessandro Sette is a consultant for Gritstone Bio, Flow Pharma, Moderna, AstraZeneca, Qiagen, Fortress, Gilead, Sanofi, Merck, RiverVest, MedaCorp, Turnstone, NA Vaccine Institute, Emervax, Gerson Lehrman Group and Guggenheim.

### **Acknowledgments**

Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number U54CA267776. We thank the Sequencing Core Facility at the La Jolla Institute for Immunology for sequencing the cDNA libraries. The NovaSeq 6000 was acquired through the Shared Instrumentation Grant Program (S10; 6000 S10OD025052). Substantive, stylistic, and copy editing of the manuscript and supplemental materials were provided by Dr. Nicole St. Denis at High-Fidelity Science Communications ([www.hifiscicomm.ca](http://www.hifiscicomm.ca)). This project has been funded in whole or in part with Federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under Contract No. 75N93021C00065 to A.S.

## 667 **References**

- 668
- 669
- 670 1 Ligon BL. Monkeypox: A review of the history and emergence in the Western hemisphere.
- 671 *Seminars Pediatric Infect Dis* 2004; 15: 280–7.
- 672 2 WHO health highlights 2022. WHO health highlights 2022. 2022; published online Dec 22.
- 673 <https://www.who.int/news-room/spotlight/health-highlights-2022> (accessed Jan 31, 2023).
- 674 3 Americas TLRH-. The cycle of neglect: the mpox emergency in the Americas is far from
- 675 ending. *Lancet Regional Heal - Am* 2023; 17: 100429.
- 676 4 Poland GA, Kennedy RB, Tosh PK. Prevention of monkeypox with vaccines: a rapid review.
- 677 *Lancet Infect Dis* 2022. DOI:10.1016/s1473-3099(22)00574-6.
- 678 5 Kupferschmidt K. Monkeypox vaccination plans take shape amid questions. *Science* 2022;
- 679 376: 1142–3.
- 680 6 Mahase E. Monkeypox: Single dose of smallpox vaccine offers 78% protection, UKHSA
- 681 reports. *Bmj* 2022; 379: o2829.
- 682 7 Control C for D. Preliminary JYNNEOS Vaccine Effectiveness Estimates Against Medically
- 683 Attended Mpox Disease in the U.S., August 15, 2022 – October 29, 2022 | Mpox| Poxvirus |
- 684 CDC. 2022; published online Dec 8. [https://www.cdc.gov/poxvirus/monkeypox/cases-](https://www.cdc.gov/poxvirus/monkeypox/cases-data/mpx-JYENOS-vaccine-effectiveness.html)
- 685 [data/mpx-JYENOS-vaccine-effectiveness.html](https://www.cdc.gov/poxvirus/monkeypox/cases-data/mpx-JYENOS-vaccine-effectiveness.html) (accessed Jan 31, 2023).
- 686 8 Weltzin R, Liu J, Pugachev KV, *et al.* Clonal vaccinia virus grown in cell culture as a new
- 687 smallpox vaccine. *Nat Med* 2003; 9: 1125–30.
- 688 9 Frey SE, Newman FK, Kennedy JS, *et al.* Comparison of the safety and immunogenicity of
- 689 ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. *Vaccine* 2008; 27: 1637–
- 690 44.
- 691 10 Kupferschmidt K. Monkeypox vaccination plans take shape amid questions. *Science* 2022;
- 692 376: 1142–3.
- 693 11 Zaack LM, Lamers MM, Verstrepen BE, *et al.* Low levels of monkeypox virus-neutralizing
- 694 antibodies after MVA-BN vaccination in healthy individuals. *Nat Med* 2023; 29: 270–8.
- 695 12 Bloch EM, Sullivan DJ, Shoham S, Tobian AAR, Casadevall A, Gebo KA. The Potential Role
- 696 of Passive Antibody-Based Therapies as Treatments for Monkeypox. *Mbio* 2022; 13: e02862–
- 697 22.
- 698 13 Gilchuk I, Gilchuk P, Sapparapu G, *et al.* Cross-Neutralizing and Protective Human
- 699 Antibody Specificities to Poxvirus Infections. *Cell* 2016; 167: 684–694.e9.
- 700 14 Hammarlund E, Lewis MW, Carter SV, *et al.* Multiple diagnostic techniques identify
- 701 previously vaccinated individuals with protective immunity against monkeypox. *Nat Med*
- 702 2005; 11: 1005–11.
- 703 15 Amanna IJ, Slifka MK, Crotty S. Immunity and immunological memory following smallpox
- 704 vaccination. *Immunol Rev* 2006; 211: 320–37.
- 705 16 Benhnia MR-E-I, McCausland MM, Su H-P, *et al.* Redundancy and plasticity of neutralizing
- 706 antibody responses are cornerstone attributes of the human immune response to the
- 707 smallpox vaccine. *J Virol* 2008; 82: 3751–68.
- 708 17 Taub DD, Ershler WB, Janowski M, *et al.* Immunity from Smallpox Vaccine Persists for
- 709 Decades: A Longitudinal Study. *Am J Medicine* 2008; 121: 1058–64.

- 710 18 Welsh RM, Selin LK, Szomolanyi-Tsuda E. Immunological Memory to Viral Infections1.  
711 *Annu Rev Immunol* 2004; 22: 711-43.
- 712 19 Bray M. New Data in a 200-Year Investigation. *Clin Infect Dis* 2004; 38: 90-1.
- 713 20 Downie AW, McCarthy K. The Antibody Response in Man Following Infection with Viruses  
714 of the Pox Group III. Antibody Response in Smallpox. *J Hyg-cambridge* 1958; 56: 479-87.
- 715 21 Eichner M. Analysis of Historical Data Suggests Long-lasting Protective Effects of Smallpox  
716 Vaccination. *Am J Epidemiol* 2003; 158: 717-23.
- 717 22 El-Ad B, Roth Y, Winder A, et al. The Persistence of Neutralizing Antibodies after  
718 Revaccination against Smallpox. *J Infect Dis* 1990; 161: 446-8.
- 719 23 Tschärke DC, Woo W-P, Sakala IG, et al. Poxvirus CD8 + T-Cell Determinants and Cross-  
720 Reactivity in BALB/c Mice. *J Virol* 2006; 80: 6318-23.
- 721 24 Edghill-Smith Y, Golding H, Manischewitz J, et al. Smallpox vaccine-induced antibodies  
722 are necessary and sufficient for protection against monkeypox virus. *Nat Med* 2005; 11: 740-  
723 7.
- 724 25 Karem KL, Reynolds M, Hughes C, et al. Monkeypox-Induced Immunity and Failure of  
725 Childhood Smallpox Vaccination To Provide Complete Protection. *Clin Vaccine Immunol*  
726 2007; 14: 1318-27.
- 727 26 Gilchuk I, Gilchuk P, Sapparapu G, et al. Cross-Neutralizing and Protective Human  
728 Antibody Specificities to Poxvirus Infections. *Cell* 2016; 167: 684-694.e9.
- 729 27 Gupta NT, Adams KD, Briggs AW, Timberlake SC, Vigneault F, Kleinstein SH. Hierarchical  
730 Clustering Can Identify B Cell Clones with High Confidence in Ig Repertoire Sequencing  
731 Data. *J Immunol* 2017; 198: 2489-99.
- 732 28 Zheng GXY, Terry JM, Belgrader P, et al. Massively parallel digital transcriptional profiling  
733 of single cells. *Nat Commun* 2017; 8: 14049.
- 734 29 Hao Y, Hao S, Andersen-Nissen E, et al. Integrated analysis of multimodal single-cell data.  
735 *Cell* 2021; 184: 3573-3587.e29.
- 736 30 Grifoni A, Zhang Y, Tarke A, et al. Defining antigen targets to dissect vaccinia virus and  
737 monkeypox virus-specific T cell responses in humans. *Cell Host Microbe* 2022; 30: 1662-  
738 1670.e4.
- 739 31 Hou J, Shrivastava S, Loo HL, Wong LH, Ooi EE, Chen J. Sequential immunization induces  
740 strong and broad immunity against all four dengue virus serotypes. *Npj Vaccines* 2020; 5: 68.
- 741 32 Galson JD, Clutterbuck EA, Trück J, et al. BCR repertoire sequencing: different patterns of  
742 B-cell activation after two Meningococcal vaccines. *Immunol Cell Biol* 2015; 93: 885-95.
- 743 33 Phad GE, Pinto D, Foglierini M, et al. Clonal structure, stability and dynamics of human  
744 memory B cells and circulating plasmablasts. *Nat Immunol* 2022; 23: 1-10.
- 745 34 Yokoyama K, Su I, Tezuka T, et al. BANK regulates BCR-induced calcium mobilization by  
746 promoting tyrosine phosphorylation of IP3 receptor. *Embo J* 2002; 21: 83-92.
- 747 35 Shinnakasu R, Inoue T, Kometani K, et al. Regulated selection of germinal-center cells into  
748 the memory B cell compartment. *Nat Immunol* 2016; 17: 861-9.
- 749 36 Roychoudhuri R, Clever D, Li P, et al. BACH2 regulates CD8+ T cell differentiation by  
750 controlling access of AP-1 factors to enhancers. *Nat Immunol* 2016; 17: 851-60.
- 751 37 Barclay AN, Brown MH, Law SKA, McKnight AJ, Tomlinson MG, Merwe PA van der. The  
752 Leucocyte Antigen FactsBook. *Sect li Leucocyte Antigens* 1997; : 327-8.

- 753 38 Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-Based Vaccines Are  
754 Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus. *Viruses*  
755 2022; 14: 1960.
- 756 39 Roper RL. Characterization of the Vaccinia Virus A35R Protein and Its Role in Virulence. *J*  
757 *Virology* 2006; 80: 306–13.
- 758 40 Yefet R, Friedel N, Tamir H, et al. A35R and H3L are Serological and B Cell Markers for  
759 Monkeypox Infection. *Medrxiv* 2022; : 2022.08.22.22278946.
- 760 41 Rehm KE, Connor RF, Jones GJB, Yimbu K, Roper RL. Vaccinia virus A35R inhibits MHC  
761 class II antigen presentation. *Virology* 2010; 397: 176–86.
- 762 42 Franceschi V, Parker S, Jacca S, et al. BoHV-4-Based Vector Single Heterologous Antigen  
763 Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal Challenge. *Plos Neglect Trop*  
764 *D* 2015; 9: e0003850.
- 765 43 Fantini J, Chahinian H, Yahi N. A Vaccine Strategy Based on the Identification of an  
766 Annular Ganglioside Binding Motif in Monkeypox Virus Protein E8L. *Viruses* 2022; 14: 2531.
- 767 44 Matho MH, Maybeno M, Benhnia MR-E-I, et al. Structural and Biochemical Characterization  
768 of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5. *J Virology*  
769 2012; 86: 8050–8.
- 770 45 Matis WL, Triana A, Shapiro R, Eldred L, Polk BF, Hood AF. Dermatologic findings  
771 associated with human immunodeficiency virus infection. *J Am Acad Dermatol* 1987; 17: 746–  
772 51.
- 773 46 Gur I. The epidemiology of Molluscum contagiosum in HIV-seropositive patients: a unique  
774 entity or insignificant finding? *Int J Std Aids* 2008; 19: 503–6.
- 775 47 Konya J, Thompson CH. Molluscum Contagiosum Virus: Antibody Responses in Persons  
776 with Clinical Lesions and Seroepidemiology in a Representative Australian Population. *J*  
777 *Infect Dis* 1999; 179: 701–4.
- 778 48 Control C for D. U.S. Mpox Case Trends Reported to CDC | Mpox | Poxvirus | CDC. U.S.  
779 Mpox Case Trends Reported to CDC. 2023; published online Feb 15.
- 780 <https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html> (accessed Jan  
781 25, 2023).
- 782 49 Payne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of  
783 JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons – 43 U.S. Jurisdictions,  
784 July 31–October 1, 2022. *Morbidity Mortal Wkly Rep* 2022; 71: 1560–4.
- 785 50 Frey SE, Newman FK, Kennedy JS, et al. Clinical and immunologic responses to multiple  
786 doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge. *Vaccine*  
787 2007; 25: 8562–73.
- 788 51 Damon IK, Davidson WB, Hughes CM, et al. Evaluation of smallpox vaccines using variola  
789 neutralization. *J Gen Virology* 2009; 90: 1962–6.
- 790 52 Pittman PR, Hahn M, Lee HS, et al. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a  
791 Vaccine against Smallpox. *New Engl J Med* 2019; 381: 1897–908.
- 792 53 Trück J, Ramasamy MN, Galson JD, et al. Identification of Antigen-Specific B Cell Receptor  
793 Sequences Using Public Repertoire Analysis. *J Immunol* 2015; 194: 252–61.

- 794 54 Galson JD, Trück J, Fowler A, *et al.* Analysis of B Cell Repertoire Dynamics Following  
795 Hepatitis B Vaccination in Humans, and Enrichment of Vaccine-specific Antibody Sequences.  
796 *Ebiomedicine* 2015; 2: 2070-9.
- 797 55 Galson JD, Trück J, Fowler A, *et al.* In-Depth Assessment of Within-Individual and Inter-  
798 Individual Variation in the B Cell Receptor Repertoire. *Front Immunol* 2015; 6: 531.
- 799 56 Hoehn KB, Heiden JAV, Zhou JQ, Lunter G, Pybus OG, Kleinstejn SH. Repertoire-wide  
800 phylogenetic models of B cell molecular evolution reveal evolutionary signatures of aging  
801 and vaccination. *Proc National Acad Sci* 2019; 116: 22664-72.
- 802 57 Hoehn KB, Turner JS, Miller FI, *et al.* Human B cell lineages associated with germinal  
803 centers following influenza vaccination are measurably evolving. *Elife* 2021; 10: e70873.
- 804 58 Lin K, Zhou Y, Ai J, *et al.* B cell receptor signatures associated with strong and poor SARS-  
805 CoV-2 vaccine responses. *Emerg Microbes Infec* 2022; 11: 452-64.
- 806 59 Coelho CH, Nadakal ST, Hurtado PAG, *et al.* Antimalarial antibody repertoire defined by  
807 plasma IG proteomics and single B cell IG sequencing. *Jci Insight* 2020; 5: e143471.
- 808 60 Galson JD, Pollard AJ, Trück J, Kelly DF. Studying the antibody repertoire after  
809 vaccination: practical applications. *Trends Immunol* 2014; 35: 319-31.
- 810 61 Hagan T, Gerritsen B, Tomalin LE, *et al.* Transcriptional atlas of the human immune  
811 response to 13 vaccines reveals a common predictor of vaccine-induced antibody responses.  
812 *Nat Immunol* 2022; 23: 1788-98.
- 813 62 Benhnia MR-E-I, McCausland MM, Su H-P, *et al.* Redundancy and plasticity of neutralizing  
814 antibody responses are cornerstone attributes of the human immune response to the  
815 smallpox vaccine. *J Virol* 2008; 82: 3751-68.
- 816 63 Davies DH, Molina DM, Wrarmert J, *et al.* Proteome-wide analysis of the serological  
817 response to vaccinia and smallpox. *Proteomics* 2007; 7: 1678-86.
- 818 64 Kennedy RB, Ovsyannikova IG, Haralambieva IH, Grill DE, Poland GA. Proteomic  
819 assessment of humoral immune responses in smallpox vaccine recipients. *Vaccine* 2022; 40:  
820 789-97.
- 821 65 Patrono LV, Pléh K, Samuni L, *et al.* Monkeypox virus emergence in wild chimpanzees  
822 reveals distinct clinical outcomes and viral diversity. *Nat Microbiol* 2020; 5: 955-65.
- 823 66 Priyamvada L, Carson WC, Ortega E, *et al.* Serological responses to the MVA-based  
824 JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of  
825 Congo. *Vaccine* 2022; 40: 7321-7.
- 826 67 Karrer U, Sierrro S, Wagner M, *et al.* Memory Inflation: Continuous Accumulation of  
827 Antiviral CD8+ T Cells Over Time. *J Immunol* 2003; 170: 2022-9.
- 828 68 Epstein JE, Tewari K, Lyke KE, *et al.* Live Attenuated Malaria Vaccine Designed to Protect  
829 Through Hepatic CD8+ T Cell Immunity. *Science* 2011; 334: 475-80.
- 830 69 Hammarlund E, Dasgupta A, Pinilla C, Norori P, Früh K, Slifka MK. Monkeypox virus evades  
831 antiviral CD4+ and CD8+ T cell responses by suppressing cognate T cell activation. *Proc*  
832 *National Acad Sci* 2008; 105: 14567-72.
- 833 70 Anderson EJ, Lai L, Wrarmert J, *et al.* Plasmablast, Memory B Cell, CD4+ T Cell, and  
834 Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara  
835 Vaccine. *Nato Adv Sci Inst Se* 2020; 8: 69.



836 71 Nigam P, Earl PL, Americo JL, *et al.* DNA/MVA HIV-1/AIDS vaccine elicits long-lived  
837 vaccinia virus-specific immunity and confers protection against a lethal monkeypox  
838 challenge. *Virology* 2007; 366: 73-83.  
839 72 Volz A, Sutter G. Chapter Five Modified Vaccinia Virus Ankara History, Value in Basic  
840 Research, and Current Perspectives for Vaccine Development. *Adv Virus Res* 2017; 97: 187-  
841 243.  
842